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LETTERS TO THE EDITOR
Guidelines For Thrombolytic Therapy
The article by Lengyel et al. (1) on guidelines for thrombolytic therapy
of thrombosed prosthetic valves is thorough and practical. However,
their conclusion that thrombolysis is not indicated as initial therapy of
patients in functional class I or II does not appear to follow from the
data they have presented. The authors state that “the reasoning against
thrombolysis in patients in functional class I or II is based on the
relatively low surgical mortality in this group as opposed to the embolic
risk of 12% to 17% caused by thrombolysis.” However, in the next
sentence, they point out that in 32 patients presenting in class I or II
treated with thrombolytic therapy, there was an 88% success rate, 3%
(one patient) major stroke rate, and zero mortality, whereas the lowest
reported surgical mortality rate in a similar group is 5%. The major
neurologic complication rate after cardiac surgery is about 3%, with a
total neurologic complication rate of 6% (2). The authors then
recommend use of heparin and warfarin but present no data on its
efficacy. They do present data on the use of heparin alone and report
a 63% success rate, two cases of cerebral embolism, and one fatal
stroke. The complication rates for these three approaches as presented
in this review and from the literature is summarized in Table 1.
Comparison of these data suggests that the lowest risk approach is
to treat initially class I and class II patients with thrombolysis.
Therefore, at our institution, we continue to favor the use of throm-
bolytic therapy initially in stable patients with St. Jude bileaflet valves
(3). Heparin is used in stable patients with contraindications to
thrombolytic therapy. Surgery is reserved for patients unresponsive to
thrombolysis or heparin therapy and for hemodynamically unstable
patients. The primary reason for this latter decision is that patients
must be stable enough to tolerate 24–72 h of thrombolytic therapy.
STEVEN S. KHAN, MD
Department of Cardiothoracic Surgery
Cedars-Sinai School of Medicine
Room 6215
8700 Beverly Boulevard
Los Angeles, California 90048-1865
E-mail: khan@csmc.edu
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Reply
We thank Khan for his letter regarding our guidelines (1). Based on his
center’s experience and our own more recent experience of 18 patients
with the treatment of nonobstructive prosthetic valve thrombosis
(PVT), I agree with their conclusion advocating fibrinolytic therapy.
The main message of our guideline was to extend the classical
indications of fibrinolysis in left-sided PVT from the critically ill to the
less sick patients.
I may remind Khan that our report summarized the results of a
consensus meeting held in 1994. The data on nonobstructive PVT were
scarce compared to the data on obstructive PVT at that time. The
literature now clearly suggests a higher success rate but still a less
evident complication rate in nonobstructive PVT. Embolic complica-
tions of thrombolysis are probably more associated with the amount of
thrombus as defined by transesophageal echocardiography (TEE) than
with its hemodynamic consequence. Khan and his group had not
reported the use of TEE but they suggested that the high efficacy and
safety of fibrinolysis would be confined to the St. Jude valve (2).
However, we could not find such a correlation in the literature.
In some instances, heparin and warfarin may be a logical choice of
treatment for patients presenting with inadequate anticoagulation in a
stable hemodynamic state or having contraindications to thrombolysis.
The latter is the case in most patients presenting with nonobstructive
PVT: stroke or recent cardiac surgery (3–5). Interestingly, Khan and
his center used heparin successfully even in obstructive PVT and they
considered heparin as a sole agent (2). Unfortunately, the success and
safety of heparin or warfarin is quite variable in different reports. The
size of thrombus again appears to play a decisive role: thrombi smaller
than 5 mm tend to resolve without complications in contrast to larger
thrombi (3,4).
The possibility of using fibrinolysis either as a first choice in
nonobstructive PVT or as a secondary treatment following unsuccess-
ful heparin therapy after 48 h was not excluded in our guidelines. We
showed that the decision as to which therapeutic modality should be
used depends on several factors such as clinical presentation, antico-
agulation status, local surgical expertise, contraindications to throm-
bolysis and importantly TEE findings. For example, a patient with
prosthetic valve obstruction but no TEE evidence of thrombus should
not be exposed to the bleeding complications or the deferral of surgery
by using thrombolysis. Moreover, it seems to me unjustified to deny a
patient the benefits of thrombolytic treatment who has PVT but not on
a St. Jude valve.
In conclusion, the question of treatment of nonobstructive PVT is
still open and more data are needed for the selection of patients for
either thrombolysis or anticoagulant treatment.
MARIA LENGYEL, MD, FACC
Hungarian Institute of Cardiology
H-1450, Budapest, P.O. Box 88
Hungary
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Table 1. Complication Rates of Three Therapies
Therapy Success (%) Death (%) Stroke (%)
Thrombolysis 88 0 3
Surgery (100) 5 (3)
Heparin 66 5 10*
*Described as “minor cerebral embolism.”
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Passive Smoking and Heart Disease
The recent review article by A. Judson Wells on the association
between heart disease and passive smoking in the work place attempts
to compile good data on a very important public health issue. The risks
of passive smoke exposure in the work place have recently received a
great deal of attention, such as the recent class action suit by flight
attendants. However, I found the data in this review article extremely
hard to interpret as nowhere in the Methods or Results was heart
disease defined.
The authors did spend some time explaining that the definition for
passive smoke exposure varies from study to study, but the other part
of the equation is the definition of outcome—in this case, heart
disease. It is unclear whether heart disease was defined as chest pain,
angina, nonfatal myocardial infarction or cardiac death.
Although the physiologic mechanisms for the association between
passive smoking and heart disease have been eloquently explained
(1,2), a lack of a definition for heart disease in the Wells study
diminishes the usefulness of the findings.
RITA F. REDBERG, MD, MSC, FACC
Echocardiography Laboratory
University of California, San Francisco
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Reply
Dr. Redberg (1) has raised a question as to what the heart disease
endpoints were in the various epidemiologic studies that were included
in my report on heart disease and passive smoking at work (2). The
abbreviated endpoints for the earlier studies are given in Table 1 of my
1994 report (3), and those for the later studies are given in Table A1
of the 1998 report (2). Because these details may be difficult to ferret
out, a more descriptive statement of the endpoints for the workplace
studies listed in Table 1 of reference 2 are: He, et al., nonfatal coronary
heart disease, defined as myocardial infarction or coronary stenosis
confirmed by coronary arteriography; Kawachi, et al., nonfatal coro-
nary heart disease; Butler, fatal ischemic heart disease; Svendsen et al.,
fatal plus nonfatal coronary heart disease event; Jackson, nonfatal
myocardial infarction; Muscat and Wynder, nonfatal myocardial in-
farction; Dobson et al., fatal or nonfatal definite or possible myocardial
infarction or coronary death; Steenland, et al., fatal coronary heart
disease, also denoted as ICD 410-414.
A. JUDSON WELLS, PHD
5 Ingleton Circle
Kennett Square, Pennsylvania 19348
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Significant Arrhythmias During Pericarditis
Are Due To Concomitant Heart Disease
Danias et al. (1) contribute an important set of observations regarding
spontaneous conversion of atrial fibrillation to sinus rhythm. I have no
quarrel with their excellent work but including pericarditis as a cause
(“underlying systemic disorder”) of significant rhythm disturbances has
been repeatedly shown to be erroneous. (The sterile pericarditis model
for induction of atrial arrhythmias has artificial experimental condi-
tions without clinical counterparts [2].) A prospective series of 100
consecutive patients with acute pericarditis continuously monitored for
arrhythmia (conservatively defined as 6 ectopic beats per minute or
anything worse) (3) and another series of 50 consecutive patients with
acute pericarditis having 24-h Holter monitoring (4) each showed
significant arrhythmia (same definition) only in patients with addi-
tional heart disease. Elegant postmortem investigations of the cardiac
conduction system showed that all patients with pericarditis and
significant arrhythmias had also had disease of the myocardium or
valves (5). Of course, significant myocarditis in the syndrome of
myopericarditis can be taken as sufficient heart disease to provoke
arrhythmias, but in such cases myocardial involvement is evident (6,7).
These remarks are only to correct a traditional assumption that
seems prevalent despite the evidence to the contrary. (This point will
be discussed in a Core Curriculum session at the College meeting in
Atlanta). The clinical pearl is: if your patient with arrhythmia has
pericarditis, look carefully for heart disease.
DAVID H. SPODICK, MD, DSC
Cardiology Division
Saint Vincent Hospital
25 Winthrop Street
Worcester, Massachusetts 01604-4593
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